Cost effectiveness and resource allocation : C/E

Keyphrases

Publications

volume 21, number 1, 2023

Iris Megido, Yael Sela, Keren Grinberg
Cost effectiveness of home care versus hospital care: a retrospective analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Anna-Janina Stephan, Marion de Lepper, Regine Wölle, Agnes Luzak, Wei Wang, Christian Jacob, Kim Maren Schneider, Horst Buxmann, Rangmar Goelz, Klaus Hamprecht, Peter Kummer, Susanne Modrow, Wolfgang Greiner, Miriam Reuschenbach
Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Pierluigi Pironti, Andrea Ambrosanio, Valeria Vismara, Marco Viganò, Eugenia Bucci, Paolo Sirtori, Giuseppe M Peretti, Laura Mangiavini
One-stage vs two-stage bilateral THA in Lombardy: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
NourolHoda Fakhrzad, Mohsen Barouni, Reza Goudarzi, Javad Kojuri, Yunes Jahani, Mohammad Tasavon Gholamhoseini
Cost-effectiveness analysis of coronary arteries bypass grafting (CABG) and percutaneous coronary intervention (PCI) through drug stent in iran: a comparative study. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Dolores Isla, Marta Lopez-Brea, María Espinosa, Natalia Arrabal, Diego Pérez-Parente, David Carcedo, Reyes Bernabé-Caro
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Maredza Mandy, Khan Kamran, Ioana R Marian, Susan J Dutton, Williamson Esther, Sarah E Lamb, Petrou Stavros
Economic costs, health-related quality of life outcomes and cost-utility of a physical and psychological group intervention targeted at older adults with neurogenic claudication. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Pierluigi Pironti, Andrea Ambrosanio, Valeria Vismara, Marco Viganò, Eugenia Bucci, Paolo Sirtori, Giuseppe M Peretti, Laura Mangiavini
Correction: One-stage vs two-stage bilateral THA in Lombardy: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Zahra Goudarzi, Mehrdad Mostafavi, Mahmood Salesi, Mojtaba Jafari, Iman Mirian, Amir Hashemi Meshkini, Khosro Keshavarz, Younes Ghasemi
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Mehdi Raadabadi, Rajabali Daroudi, Kazem Zendehdel, Ali Akbar Haghdoost, Mohammad Reza Ebadzadeh, Hamideh Rashidian
Direct and indirect medical costs of bladder cancer in Iran. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Pierluigi Pironti, Andrea Ambrosanio, Valeria Vismara, Marco Viganò, Eugenia Bucci, Paolo Sirtori, Giuseppe M Peretti, Laura Mangiavini
One-stage vs two-stage bilateral THA in Lombardy: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Igor Larrañaga, Oliver Ibarrondo, Lorea Mar-Barrutia, Myriam Soto-Gordoa, Javier Mar
Excess healthcare costs of mental disorders in children, adolescents and young adults in the Basque population registry adjusted for socioeconomic status and sex. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
John S Phillips, Jacob Newman
Quantifying the direct cost benefits of vestibular telemetry using the CAVA system to diagnose the causes of dizziness. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Qiuling Zhao, Ruixiang Xie, Wanfu Zhong, Wenbin Liu, Ting Chen, Xiuliang Qiu, Lin Yang
Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Lorna Guinness, Angela Kairu, August Kuwawenaruwa, Karima Khalid, Khamis Awadh, Vincent Were, Edwine Barasa, Hiral Shah, Peter Baker, Carl Otto Schell, Tim Baker
Essential emergency and critical care as a health system response to critical illness and the COVID19 pandemic: what does it cost? Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Lorna Guinness, Angela Kairu, August Kuwawenaruwa, Karima Khalid, Khamis Awadh, Vincent Were, Edwine Barasa, Hiral Shah, Peter Baker, Carl Otto Schell, Tim Baker
Essential emergency and critical care as a health system response to critical illness and the COVID19 pandemic: what does it cost? Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Yasuhiro Morii, Kagari Abiko, Toshiya Osanai, Jiro Takami, Takumi Tanikawa, Kensuke Fujiwara, Kiyohiro Houkin, Katsuhiko Ogasawara
Cost-effectiveness of seven-days-per-week rehabilitation schedule for acute stroke patients. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling
Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Anna-Janina Stephan, Marion de Lepper, Regine Wölle, Agnes Luzak, Wei Wang, Christian Jacob, Kim Maren Schneider, Horst Buxmann, Rangmar Goelz, Klaus Hamprecht, Peter Kummer, Susanne Modrow, Wolfgang Greiner, Miriam Reuschenbach
Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Yasuhiro Morii, Kagari Abiko, Toshiya Osanai, Jiro Takami, Takumi Tanikawa, Kensuke Fujiwara, Kiyohiro Houkin, Katsuhiko Ogasawara
Cost-effectiveness of seven-days-per-week rehabilitation schedule for acute stroke patients. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Dolores Isla, Marta Lopez-Brea, María Espinosa, Natalia Arrabal, Diego Pérez-Parente, David Carcedo, Reyes Bernabé-Caro
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Jiahe Li, Lichang Liu, Haijun Cao, Mei Yang, Xin Sun
Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in "Boao Lecheng Pilot Zone". Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Fernando Henrique de Albuquerque Maia, Luciana Martins Rozman, Heloisa de Andrade Carvalho, Patricia Coelho De Soárez
Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Jiahe Li, Lichang Liu, Haijun Cao, Mei Yang, Xin Sun
Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in "Boao Lecheng Pilot Zone". Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Zaixing Wang, Chunling Liu, Baoying Tan, Guoqing Sun, Poucheok Pang, Kangchen Lv, Hui Xie, Xiong Ou, Xianhai Zeng, Jianwei Xuan
Clinical and economic benefits of image-guided system in functional endoscopicsinus surgery: a retrospective chart review study in China. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
John S Phillips, Jacob Newman
Quantifying the direct cost benefits of vestibular telemetry using the CAVA system to diagnose the causes of dizziness. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Mojtaba Shafiekhani, Tahmoores Niknam, Seyed Ahmad Tara, Parviz Mardani, Khatereh Mirzad Jahromi, Sedigheh Jafarian, Sara Arabsheybani, Halimeh Negahban, Majid Hamzehnejadi, Zahra Zare, Khadijeh Ghaedi Ghalini, Ali Ghasemnezhad, Mahmoud Akbari, Reza Shahriarirad, Seyed Ali MalekHosseini
COVID-19 versus applied infection control policies in a Major Transplant Center in Iran. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
John S Phillips, Jacob Newman
Quantifying the direct cost benefits of vestibular telemetry using the CAVA system to diagnose the causes of dizziness. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Qiuling Zhao, Ruixiang Xie, Wanfu Zhong, Wenbin Liu, Ting Chen, Xiuliang Qiu, Lin Yang
Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Mojtaba Shafiekhani, Tahmoores Niknam, Seyed Ahmad Tara, Parviz Mardani, Khatereh Mirzad Jahromi, Sedigheh Jafarian, Sara Arabsheybani, Halimeh Negahban, Majid Hamzehnejadi, Zahra Zare, Khadijeh Ghaedi Ghalini, Ali Ghasemnezhad, Mahmoud Akbari, Reza Shahriarirad, Seyed Ali MalekHosseini
COVID-19 versus applied infection control policies in a Major Transplant Center in Iran. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Igor Larrañaga, Oliver Ibarrondo, Lorea Mar-Barrutia, Myriam Soto-Gordoa, Javier Mar
Excess healthcare costs of mental disorders in children, adolescents and young adults in the Basque population registry adjusted for socioeconomic status and sex. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
John S Phillips, Jacob Newman
Quantifying the direct cost benefits of vestibular telemetry using the CAVA system to diagnose the causes of dizziness. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
NourolHoda Fakhrzad, Mohsen Barouni, Reza Goudarzi, Javad Kojuri, Yunes Jahani, Mohammad Tasavon Gholamhoseini
Cost-effectiveness analysis of coronary arteries bypass grafting (CABG) and percutaneous coronary intervention (PCI) through drug stent in iran: a comparative study. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Maredza Mandy, Khan Kamran, Ioana R Marian, Susan J Dutton, Williamson Esther, Sarah E Lamb, Petrou Stavros
Economic costs, health-related quality of life outcomes and cost-utility of a physical and psychological group intervention targeted at older adults with neurogenic claudication. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Qiuling Zhao, Ruixiang Xie, Wanfu Zhong, Wenbin Liu, Ting Chen, Xiuliang Qiu, Lin Yang
Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling
Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Yasuhiro Morii, Kagari Abiko, Toshiya Osanai, Jiro Takami, Takumi Tanikawa, Kensuke Fujiwara, Kiyohiro Houkin, Katsuhiko Ogasawara
Cost-effectiveness of seven-days-per-week rehabilitation schedule for acute stroke patients. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Zahra Goudarzi, Mehrdad Mostafavi, Mahmood Salesi, Mojtaba Jafari, Iman Mirian, Amir Hashemi Meshkini, Khosro Keshavarz, Younes Ghasemi
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Iris Megido, Yael Sela, Keren Grinberg
Cost effectiveness of home care versus hospital care: a retrospective analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Pierluigi Pironti, Andrea Ambrosanio, Valeria Vismara, Marco Viganò, Eugenia Bucci, Paolo Sirtori, Giuseppe M Peretti, Laura Mangiavini
Correction: One-stage vs two-stage bilateral THA in Lombardy: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Pierluigi Pironti, Andrea Ambrosanio, Valeria Vismara, Marco Viganò, Eugenia Bucci, Paolo Sirtori, Giuseppe M Peretti, Laura Mangiavini
Correction: One-stage vs two-stage bilateral THA in Lombardy: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Anna-Janina Stephan, Marion de Lepper, Regine Wölle, Agnes Luzak, Wei Wang, Christian Jacob, Kim Maren Schneider, Horst Buxmann, Rangmar Goelz, Klaus Hamprecht, Peter Kummer, Susanne Modrow, Wolfgang Greiner, Miriam Reuschenbach
Healthcare costs of congenital cytomegalovirus (cCMV) disease in infants during the first two years of life: a retrospective German claims database analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Hongyu Gong, Siew Chin Ong, Fan Li, Zhiying Weng, Keying Zhao, Zhengyou Jiang
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Fernando Henrique de Albuquerque Maia, Luciana Martins Rozman, Heloisa de Andrade Carvalho, Patricia Coelho De Soárez
Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Pierluigi Pironti, Andrea Ambrosanio, Valeria Vismara, Marco Viganò, Eugenia Bucci, Paolo Sirtori, Giuseppe M Peretti, Laura Mangiavini
One-stage vs two-stage bilateral THA in Lombardy: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Augustovski Federico, Bardach Ariel, Santoro Adrián, Rodriguez-Cairoli Federico, López-Osornio Alejandro, Argento Fernando, Havela Maissa, Blumenfeld Alejandro, Ballivian Jamile, Solioz Germán, Capula Analía, López Analía, Cejas Cintia, Savedoff William, Palacios Alfredo, Rubinstein Adolfo, Pichon-Riviere Andrés
Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Hongyu Gong, Siew Chin Ong, Fan Li, Zhiying Weng, Keying Zhao, Zhengyou Jiang
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Jiahe Li, Lichang Liu, Haijun Cao, Mei Yang, Xin Sun
Use of real-world evidence to support regulatory decisions on medical devices in China and a unique opportunity to gain accelerated approval in "Boao Lecheng Pilot Zone". Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Mehdi Raadabadi, Rajabali Daroudi, Kazem Zendehdel, Ali Akbar Haghdoost, Mohammad Reza Ebadzadeh, Hamideh Rashidian
Direct and indirect medical costs of bladder cancer in Iran. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Zaixing Wang, Chunling Liu, Baoying Tan, Guoqing Sun, Poucheok Pang, Kangchen Lv, Hui Xie, Xiong Ou, Xianhai Zeng, Jianwei Xuan
Clinical and economic benefits of image-guided system in functional endoscopicsinus surgery: a retrospective chart review study in China. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Zaixing Wang, Chunling Liu, Baoying Tan, Guoqing Sun, Poucheok Pang, Kangchen Lv, Hui Xie, Xiong Ou, Xianhai Zeng, Jianwei Xuan
Clinical and economic benefits of image-guided system in functional endoscopicsinus surgery: a retrospective chart review study in China. Cost effectiveness and resource allocation : C/E 21 (1) (2023)